Ascendis Pharma (ASND) Stock Analysis & AI Equity Report
Ascendis Pharma (ASND) overview
Ascendis Pharma (ASND) stock analysis and AI equity research. For the latest completed financial year, 2025, Ascendis Pharma reported revenue of EUR 692m and operating profit of EUR -131m; the year-end share price was 213.24 EUR and market capitalisation was EUR 12,924m. Ascendis Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ascendis Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Ascendis Pharma
Ascendis Pharma A/S is a global biopharmaceutical company that develops TransCon-based therapies for endocrine rare diseases and oncology. Its portfolio includes approved products and product candidates for hypoparathyroidism and growth disorders, and it also pursues collaborations to expand TransCon applications in other therapeutic areas and markets.
Generate the Ascendis Pharma report
Ascendis Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ascendis Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.